Page 12 - Exact Sciences News Today

Exact Sciences Corporation (NASDAQ:EXAS) Q4 2023 Earnings Call Transcript February 21, 2024 Exact Sciences Corporation beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.53. Exact Sciences Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome […]

Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.

A $7.5 million grant will support Wisconsins efforts in becoming a national tech hub focused on the biohealth industry.

Exact Sciences (NASDAQ:EXAS – Get Free Report) had its price objective decreased by analysts at Canaccord Genuity Group from $100.00 to $90.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Canaccord Genuity Group’s price target would suggest a potential upside of 50.18% […]

Exact Sciences Corporation beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.53.

Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.

Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.

The market will broaden the sustenance of its rally when interest-rate cuts begin to be priced in and investors begin to think about the roadmap, an analyst said.

The University of Birmingham spin-out is working to advance cancer treatment